Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 January 2007, Vol. 109, No. 1, pp. 331-338.
Prepublished online as a Blood First Edition Paper on September 5, 2006; DOI 10.1182/blood-2006-02-001800.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Figures
Right arrow Supplemental Figures
Right arrow Erratum (v110,p1474)
Right arrow All Versions of this Article:
blood-2006-02-001800v1
109/1/331    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwaller, J.
Right arrow Articles by Huard, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwaller, J.
Right arrow Articles by Huard, B.
Related Collections
Right arrow Neoplasia
Right arrow Phagocytes
Right arrow Clinical Trials and Observations
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness

Juerg Schwaller1, Pascal Schneider2, Paulette Mhawech-Fauceglia3, Thomas McKee4, Samir Myit4, Thomas Matthes5, Jurg Tschopp1, Olivier Donze6, Frederique-Anne Le Gal7, and Bertrand Huard8,9,10,

1 Department of Research, University Hospital, Basel, Switzerland; 2 Department of Biochemistry, University of Lausanne, Lausanne, Switzerland; 3 Roswell Park Cancer Institute, Buffalo, NY; 4 Department of Pathology, University Medical Center, Geneva, Switzerland; 5 Hematology Unit, Department of Internal Medicine, University Hospital, Geneva, Switzerland; 6 Apotech Corp, Epalinges, Switzerland; 7 Department of Dermatology, University Hospital, Geneva, Switzerland; 8 Louis Jeantet Laboratory, University Medical Center, Geneva, Switzerland; 9 Department of Dermatology, University Hospital, Geneva, Switzerland; and 10 Department of Pathology-Immunology, University Hospital, Geneva, Switzerland

A PRoliferation-Inducing TNF Ligand (APRIL) costimulates B-cell activation. When overexpressed in mice, APRIL induces B-cell neoplasia, reminiscent of human B-cell chronic lymphoid leukemia (B-CLL). We analyzed APRIL expression in situ in human non-Hodgkin lymphomas. APRIL up-regulation was only observed in high-grade B-cell lymphomas, diffuse large B-cell lymphoma (DLBCL), and Burkitt lymphoma (BL). Up-regulation was seen in 46% and 20% of DLBCL and BL, respectively. In DLBCL, neutrophils, constitutively producing APRIL and infiltrating the tumor tissue, were the main cellular source of APRIL. Rare DLBCL cases showed a predominance of histiocytes or mesenchymal cells as APRIL source. APRIL secreted by neutrophils accumulated on tumor cells via proteoglycan binding. In addition to proteoglycans, DLBCL tumor cells expressed the APRIL signaling receptor, TACI and/or BCMA, indicating that these tumor cells are fully equipped to respond to APRIL. A retrospective clinical analysis revealed a significant correlation between high expression of APRIL in tumor lesions and decreased overall patient survival rate. Hence, APRIL produced by inflammatory cells infiltrating lymphoma lesions may increase tumor aggressiveness and affect disease outcome.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Virol.Home page
G. Brady, H. J. Whiteman, L. C. Spender, and P. J. Farrell
Downregulation of RUNX1 by RUNX3 Requires the RUNX3 VWRPY Sequence and Is Essential for Epstein-Barr Virus-Driven B-Cell Proliferation
J. Virol., July 1, 2009; 83(13): 6909 - 6916.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Belnoue, T. Matthes, C.-A. Siegrist, and B. Huard
Comment on "Dendritic Cells and Monocyte/Macrophages That Create the IL-6/APRIL-Rich Lymph Node Microenvironment Where Plasmablasts Mature"
J. Immunol., May 1, 2009; 182(9): 5159 - 5159.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Schuler, E. Contassot, M. Irla, S. Hugues, O. Preynat-Seauve, F. Beermann, A. Donda, L.E. French, and B. Huard
Direct Presentation of a Melanocyte-Associated Antigen in Peripheral Lymph Nodes Induces Cytotoxic CD8+ T Cells
Cancer Res., October 15, 2008; 68(20): 8410 - 8418.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
L. Planelles, S. Castillo-Gutierrez, J. P. Medema, A. Morales-Luque, H. Merle-Beral, and M. Hahne
APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival
Haematologica, September 1, 2007; 92(9): 1284 - 1285.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020